Novel extended in vitro-in vivo correlation model for the development of extended-release formulations for baclofen: From formulation composition to in vivo pharmacokinetics

被引:16
作者
Kim, Tae Hwan [1 ]
Bulitta, Jurgen B. [2 ]
Kim, Do-Hyung [3 ]
Shin, Soyoung [4 ]
Shin, Beom Soo [5 ]
机构
[1] Daegu Catholic Univ, Coll Pharm, Gyongsan 38430, Gyeongbuk, South Korea
[2] Univ Florida, Coll Pharm, Orlando, FL 32827 USA
[3] KNOTUS Co Ltd, Res Ctr, Guri 11910, Gyeonggi, South Korea
[4] Wonkwang Univ, Coll Pharm, 460 Iksan Daero, Iksan 54538, Jeonbuk, South Korea
[5] Sungkyunkwan Univ, Sch Pharm, Suwon, Gyeonggi, South Korea
基金
新加坡国家研究基金会;
关键词
Extended-release formulation; In vitro-in vivo correlation; Population pharmacokinetic model; Hydroxypropyl methylcellulose; Baclofen; INTESTINAL-ABSORPTION; POPULATION; TRANSPORT; MECHANISM; TABLETS; DESIGN; TIME;
D O I
10.1016/j.ijpharm.2018.12.007
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In vitro-in vivo correlation (IVIVC), a predictive mathematical model between the in vitro dissolution and the in vivo pharmacokinetics has been utilized for the development of new extended release (ER) formulations. The aim of the present study was to extend the IVIVC approach, which correlates among the formulation composition, the in vitro dissolution, and the plasma drug concentration, to predict plasma drug concentrations from a given composition of the formulation, and vice versa, using baclofen as a model drug. Baclofen ER tablets with different dissolution rates were prepared by varying the composition of hydroxypropyl methylcellulose (HPMC). First, the HPMC compositions and the corresponding in vitro dissolutions parameters were correlated, and then the in vitro dissolution parameters were correlated with the in vivo dissolution parameters extracted from the pharmacokinetic profiles of the baclofen ER formulations via population pharmacokinetic modeling. The final extended IVIVC model linked the composition of the formulation, the in vitro dissolution, and the in vivo plasma concentration profile and was successfully applied for the prediction of in vivo pharmacokinetics from the amount of HPMC in baclofen ER formulations. The present approach holds great promise for designing optimal compositions of ER formulations to present desired plasma concentration profile.
引用
收藏
页码:276 / 286
页数:11
相关论文
共 25 条
[1]   Population In Vitro-In Vivo Correlation Model Linking Gastrointestinal Transit Time, pH, and Pharmacokinetics: Itraconazole as a Model Drug [J].
Abuhelwa, Ahmad Y. ;
Mudge, Stuart ;
Hayes, David ;
Upton, Richard N. ;
Foster, David J. R. .
PHARMACEUTICAL RESEARCH, 2016, 33 (07) :1782-1794
[2]   Baclofen: Intestinal absorption mechanism in mice [J].
Balerio, GN ;
Rubio, MC .
GENERAL PHARMACOLOGY, 1996, 27 (07) :1269-1271
[3]   In vitro-In Vivo Correlations: Tricks and Traps [J].
Cardot, J. -M. ;
Davit, B. M. .
AAPS JOURNAL, 2012, 14 (03) :491-499
[4]   Evidence of competitive inhibition for the intestinal absorption of baclofen by phenylalanine [J].
CejudoFerragud, E ;
Nacher, A ;
Polache, A ;
CercosFortea, T ;
Merino, M ;
Casabo, VG .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1996, 132 (1-2) :63-69
[5]   LINEAR-SYSTEMS ANALYSIS IN PHARMACOKINETICS [J].
CUTLER, DJ .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1978, 6 (03) :265-282
[6]   Diverse approaches for the enhancement of oral drug bioavailability [J].
Fasinu, Pius ;
Pillay, Viness ;
Ndesendo, Valence M. K. ;
du Toit, Lisa C. ;
Choonara, Yahya E. .
BIOPHARMACEUTICS & DRUG DISPOSITION, 2011, 32 (04) :185-209
[7]  
FDA U. S., 1997, RESEARCH
[8]   Statistical Comparison of Dissolution Profiles to Predict the Bioequivalence of Extended Release Formulations [J].
Gomez-Mantilla, J. D. ;
Schaefer, U. F. ;
Casabo, V. G. ;
Lehr, T. ;
Lehr, C. M. .
AAPS JOURNAL, 2014, 16 (04) :791-801
[9]   Preparation and in vivo characterization of dual release tablet containing sarpogrelate hydrochloride [J].
Jun H. ;
Lee H.-J. ;
Shin B.-S. ;
Park C.-W. .
Journal of Pharmaceutical Investigation, 2018, 48 (3) :363-372
[10]  
Kim T.H., 2017, J PHARM INVEST